Both formulations contain semaglutide, but they differ in absorption, frequency and practical instructions. The useful comparison starts with your health and routine, then checks the evidence and full ongoing cost.
Shared ingredient, different administration
Wegovy injection is given weekly. Wegovy tablets are taken daily with specific fasting, water and waiting requirements. Those differences affect what you need to remember and organise. A person concerned about needles may prefer discussing a tablet; another may find a weekly task easier than a daily sequence. Neither preference establishes medical suitability by itself.
The milligram numbers cannot be compared as if they measure an identical delivered amount. Oral and injected semaglutide reach the body differently. Do not calculate a daily equivalent by dividing an injection dose, or compare a 25 mg tablet with a 2.4 mg injection as a simple strength ratio.
Sources: Novo Nordisk / electronic medicines compendium: Wegovy tablets: UK Summary of Product Characteristics; Novo Nordisk / electronic medicines compendium: Wegovy FlexTouch: UK Summary of Product Characteristics
Read the studies beside their questions
OASIS 4 studied the 25 mg oral formulation against placebo. STEP 1 studied the 2.4 mg injection against placebo in a different trial. The results show evidence of weight reduction under each study's conditions; they do not form a randomised head-to-head comparison between the two formats.
When a comparison claims that one is 'as good as' the other, ask what study supports that statement, which dose it tested and whether participants had diabetes. Also ask which analysis was used and whether people who stopped treatment were included. These questions can explain why two headlines quote different averages without either describing your likely outcome.
Sources: New England Journal of Medicine: OASIS 4: Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity; New England Journal of Medicine: STEP 1: Once-Weekly Semaglutide in Adults with Overweight or Obesity; European Medicines Agency: Wegovy oral formulation: European regulatory assessment report
Compare a difficult week, not only an ideal one
Think through work shifts, trips, eating patterns and other prescriptions. For an injection, discuss device use, storage and sharps. For tablets, discuss how the fasting period and delay before other oral medicines will fit. If another person helps with treatment, include them in the practical conversation with your consent.
Write down the obstacle you are trying to solve. 'I travel often' may mean refrigeration is difficult, but it may also mean the morning tablet routine is inconsistent. Naming the actual difficulty lets the prescriber discuss relevant options instead of assuming that one format is inherently more convenient.
Sources: Novo Nordisk / electronic medicines compendium: Wegovy FlexTouch: patient information leaflet; Novo Nordisk / electronic medicines compendium: Wegovy tablets: patient information leaflet
A switch needs a prescriber-led plan
The product information includes specific provisions for switching between certain doses and warns that oral absorption is more variable. That does not create a universal conversion for all injection strengths, all tablets or all treatment gaps. A clinician needs the current dose, last dose date, symptoms and reason for switching.
Ask for written instructions that identify the exact new product and start date, and what to do with the previous supply. Do not overlap treatments to avoid waste. If the switch is motivated by side effects, make sure those symptoms are assessed rather than assuming the route change will remove them.
Sources: Novo Nordisk / electronic medicines compendium: Wegovy tablets: UK Summary of Product Characteristics; Novo Nordisk / electronic medicines compendium: Wegovy FlexTouch: UK Summary of Product Characteristics
Compare the whole supply period
Put the number of doses, intended duration and repeat cost on the same line. A four-dose pen and a pack of tablets are different units. Introductory discounts, delivery charges and review fees can make a headline comparison misleading. Ask whether the price remains available at the dose the prescriber actually expects to use.
Check NHS information by formulation and location. The established injection guidance cannot automatically be extended to tablets. Ask what follow-up is included whichever route is chosen, because the practical value of a service includes getting timely advice when treatment does not go as planned.
Sources: NICE: TA875: Semaglutide for managing overweight and obesity; Scottish Medicines Consortium: Semaglutide tablets: NHS Scotland non-submission advice, September 2026; General Pharmaceutical Council and UK health organisations: How to keep safe when getting medicines or treatment online
Questions, answered.
Can the tablet remove all semaglutide side effects?
No. The tablet contains the same active medicine and has its own safety information. A change in route needs an individual discussion.
Sources: Novo Nordisk / electronic medicines compendium: Wegovy tablets: patient information leaflet
Is the daily tablet automatically easier to use?
That depends on the person. Consider the full fasting and waiting routine alongside the weekly injection's device and storage requirements.
Sources: Novo Nordisk / electronic medicines compendium: Wegovy tablets: patient information leaflet; Novo Nordisk / electronic medicines compendium: Wegovy FlexTouch: patient information leaflet
Sources & further reading
Original sources for this guide. Source checks are not independent clinical review.
- Wegovy tablets: UK Summary of Product CharacteristicsNovo Nordisk / electronic medicines compendium · Accessed 19 November 2026
- Wegovy FlexTouch: UK Summary of Product CharacteristicsNovo Nordisk / electronic medicines compendium · Accessed 19 November 2026
- OASIS 4: Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or ObesityNew England Journal of Medicine · Accessed 19 November 2026
- STEP 1: Once-Weekly Semaglutide in Adults with Overweight or ObesityNew England Journal of Medicine · Accessed 19 November 2026
- Wegovy oral formulation: European regulatory assessment reportEuropean Medicines Agency · Accessed 19 November 2026
- Wegovy FlexTouch: patient information leafletNovo Nordisk / electronic medicines compendium · Accessed 19 November 2026
- Wegovy tablets: patient information leafletNovo Nordisk / electronic medicines compendium · Accessed 19 November 2026
- TA875: Semaglutide for managing overweight and obesityNICE · Accessed 19 November 2026
- Semaglutide tablets: NHS Scotland non-submission advice, September 2026Scottish Medicines Consortium · Accessed 19 November 2026
- How to keep safe when getting medicines or treatment onlineGeneral Pharmaceutical Council and UK health organisations · Accessed 19 November 2026
